The approval of Sotorasib for treating KRASG12C NSCLC represents a noteworthy achievement as the initial targeted therapy for tumors harboring KRAS mutations, offering hopeful prospects for the advancement of similar allele-specific treatments for mutant RAS [244]. Here, KRAS is linked to non-small cell lung carcinoma.